Eaton Vance Worldwide Health Sciences Fund Buys Merck Inc, GlaxoSmithKline PLC, Novartis AG, Sells AbbVie Inc, Bristol-Myers Squibb Company, Biogen Inc

Author's Avatar
insider
Aug 01, 2018
Article's Main Image
Investment company Eaton Vance Worldwide Health Sciences Fund buys Merck Inc, GlaxoSmithKline PLC, Novartis AG, Lonza Group, Medtronic PLC, Masimo Corp, Abbott Laboratories, bluebird bio Inc, Coloplast A/S, Atara Biotherapeutics Inc, sells AbbVie Inc, Bristol-Myers Squibb Company, Biogen Inc, Gilead Sciences Inc, Roche Holding AG during the 3-months ended 2018-05-31, according to the most recent filings of the investment company, Eaton Vance Worldwide Health Sciences Fund. As of 2018-05-31, Eaton Vance Worldwide Health Sciences Fund owns 60 stocks with a total value of $986 million. These are the details of the buys and sells.

For the details of Eaton Vance Worldwide Health Sciences Fund's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Eaton+Vance+Worldwide+Health+Sciences+Fund

These are the top 5 holdings of Eaton Vance Worldwide Health Sciences Fund
  1. Johnson & Johnson (JNJ) - 496,664 shares, 6.02% of the total portfolio.
  2. UnitedHealth Group Inc (UNH) - 239,444 shares, 5.86% of the total portfolio. Shares reduced by 14.83%
  3. Pfizer Inc (PFE) - 1,135,385 shares, 4.14% of the total portfolio.
  4. Merck & Co Inc (MRK) - 658,673 shares, 3.98% of the total portfolio. Shares added by 241.28%
  5. Bayer AG (BAYN) - 253,183 shares, 3.06% of the total portfolio. Shares reduced by 16.06%
New Purchase: GlaxoSmithKline PLC (GSK)

Eaton Vance Worldwide Health Sciences Fund initiated holding in GlaxoSmithKline PLC. The purchase prices were between $12.74 and $15.25, with an estimated average price of $14.14. The stock is now traded at around $15.82. The impact to a portfolio due to this purchase was 2.68%. The holding were 1,306,141 shares as of 2018-05-31.

New Purchase: Novartis AG (NVS)

Eaton Vance Worldwide Health Sciences Fund initiated holding in Novartis AG. The purchase prices were between $74.96 and $84.29, with an estimated average price of $79.19. The stock is now traded at around $83.69. The impact to a portfolio due to this purchase was 2.22%. The holding were 295,000 shares as of 2018-05-31.

New Purchase: Lonza Group Ltd (LONN)

Eaton Vance Worldwide Health Sciences Fund initiated holding in Lonza Group Ltd. The purchase prices were between $219.8 and $271.6, with an estimated average price of $244.03. The stock is now traded at around $305.30. The impact to a portfolio due to this purchase was 1.51%. The holding were 55,571 shares as of 2018-05-31.

New Purchase: Medtronic PLC (MDT)

Eaton Vance Worldwide Health Sciences Fund initiated holding in Medtronic PLC. The purchase prices were between $76.55 and $86.99, with an estimated average price of $81.47. The stock is now traded at around $90.24. The impact to a portfolio due to this purchase was 1.03%. The holding were 117,565 shares as of 2018-05-31.

New Purchase: Masimo Corp (MASI)

Eaton Vance Worldwide Health Sciences Fund initiated holding in Masimo Corp. The purchase prices were between $83.58 and $100.22, with an estimated average price of $90.61. The stock is now traded at around $100.06. The impact to a portfolio due to this purchase was 0.59%. The holding were 58,354 shares as of 2018-05-31.

New Purchase: bluebird bio Inc (BLUE)

Eaton Vance Worldwide Health Sciences Fund initiated holding in bluebird bio Inc. The purchase prices were between $160.45 and $233.05, with an estimated average price of $183.75. The stock is now traded at around $155.50. The impact to a portfolio due to this purchase was 0.26%. The holding were 14,429 shares as of 2018-05-31.

Added: Merck & Co Inc (MRK)

Eaton Vance Worldwide Health Sciences Fund added to a holding in Merck & Co Inc by 241.28%. The purchase prices were between $53.27 and $60.25, with an estimated average price of $56.93. The stock is now traded at around $65.49. The impact to a portfolio due to this purchase was 2.81%. The holding were 658,673 shares as of 2018-05-31.

Added: Abbott Laboratories (ABT)

Eaton Vance Worldwide Health Sciences Fund added to a holding in Abbott Laboratories by 37.48%. The purchase prices were between $57.57 and $63.62, with an estimated average price of $60.36. The stock is now traded at around $64.78. The impact to a portfolio due to this purchase was 0.47%. The holding were 276,884 shares as of 2018-05-31.

Added: Coloplast A/S (COLO B)

Eaton Vance Worldwide Health Sciences Fund added to a holding in Coloplast A/S by 33.59%. The purchase prices were between $496.4 and $617.2, with an estimated average price of $539.65. The stock is now traded at around $707.80. The impact to a portfolio due to this purchase was 0.25%. The holding were 104,124 shares as of 2018-05-31.

Added: Neurocrine Biosciences Inc (NBIX)

Eaton Vance Worldwide Health Sciences Fund added to a holding in Neurocrine Biosciences Inc by 72.52%. The purchase prices were between $75.3 and $95.64, with an estimated average price of $85.02. The stock is now traded at around $113.55. The impact to a portfolio due to this purchase was 0.24%. The holding were 59,473 shares as of 2018-05-31.

Sold Out: Pacira Pharmaceuticals Inc (PCRX)

Eaton Vance Worldwide Health Sciences Fund sold out a holding in Pacira Pharmaceuticals Inc. The sale prices were between $27.5 and $36.7, with an estimated average price of $33.21.

Sold Out: AveXis Inc (AVXS)

Eaton Vance Worldwide Health Sciences Fund sold out a holding in AveXis Inc. The sale prices were between $115.91 and $217.83, with an estimated average price of $172.63.

Reduced: AbbVie Inc (ABBV)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in AbbVie Inc by 59.34%. The sale prices were between $89.78 and $119.75, with an estimated average price of $101.49. The stock is now traded at around $93.91. The impact to a portfolio due to this sale was -2.57%. Eaton Vance Worldwide Health Sciences Fund still held 156,151 shares as of 2018-05-31.

Reduced: Bristol-Myers Squibb Company (BMY)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Bristol-Myers Squibb Company by 68.88%. The sale prices were between $50.53 and $67.92, with an estimated average price of $57.67. The stock is now traded at around $59.62. The impact to a portfolio due to this sale was -2.51%. Eaton Vance Worldwide Health Sciences Fund still held 176,060 shares as of 2018-05-31.

Reduced: Biogen Inc (BIIB)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Biogen Inc by 41.54%. The sale prices were between $257.52 and $294.4, with an estimated average price of $274.38. The stock is now traded at around $344.06. The impact to a portfolio due to this sale was -1.28%. Eaton Vance Worldwide Health Sciences Fund still held 63,797 shares as of 2018-05-31.

Reduced: Gilead Sciences Inc (GILD)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Gilead Sciences Inc by 25.24%. The sale prices were between $64.88 and $81.72, with an estimated average price of $72.89. The stock is now traded at around $77.90. The impact to a portfolio due to this sale was -0.98%. Eaton Vance Worldwide Health Sciences Fund still held 378,226 shares as of 2018-05-31.

Reduced: Roche Holding AG (ROG)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Roche Holding AG by 42.99%. The sale prices were between $211.05 and $229.8, with an estimated average price of $220.64. The stock is now traded at around $243.05. The impact to a portfolio due to this sale was -0.96%. Eaton Vance Worldwide Health Sciences Fund still held 56,527 shares as of 2018-05-31.

Reduced: Shire PLC (SHP)

Eaton Vance Worldwide Health Sciences Fund reduced to a holding in Shire PLC by 43.99%. The sale prices were between $29.54 and $42.19, with an estimated average price of $36.76. The stock is now traded at around $43.51. The impact to a portfolio due to this sale was -0.79%. Eaton Vance Worldwide Health Sciences Fund still held 240,939 shares as of 2018-05-31.



Here is the complete portfolio of Eaton Vance Worldwide Health Sciences Fund. Also check out:

1. Eaton Vance Worldwide Health Sciences Fund's Undervalued Stocks
2. Eaton Vance Worldwide Health Sciences Fund's Top Growth Companies, and
3. Eaton Vance Worldwide Health Sciences Fund's High Yield stocks
4. Stocks that Eaton Vance Worldwide Health Sciences Fund keeps buying
Rating:
0 / 5 (0 votes)
Author's Avatar
WRITTEN BY

Request A Demo

Learn more about GuruFocus' key features, including All-In-One Screener, backtesting, 30-year financial, stock summary page, guru trades, insider trades, excel Add-in, google sheets and much more.

GuruFocus Screeners

Related Articles